Tumour necrosis factor alpha in severe congestive cardiac failure.

  • Dutka D
  • Elborn J
  • Delamere F
  • et al.
N/ACitations
Citations of this article
9Readers
Mendeley users who have this article in their library.

Abstract

OBJECTIVE To examine the concentration of circulating tumour necrosis factor alpha (TNF alpha) in patients with severe congestive heart failure (New York Heart Association class IV) during one year and to correlate changes in this cytokine with changes in plasma noradrenaline, plasma renin activity, and weight. DESIGN A prospective study of the role of TNF alpha in severe chronic heart failure. Blood samples were collected at intervals of three months. SETTING Medical research centre of a teaching hospital. PATIENTS 16 patients with chronic stable severe heart failure. INTERVENTIONS Vasodilator treatment with captopril or flosequinan. MAIN OUTCOME MEASURES Changes in TNF alpha and the correlation with changes in plasma noradrenaline, plasma renin activity, and weight during optimal medical treatment for one year. RESULTS The mean concentration of TNF alpha was greater than the upper 95% confidence interval for healthy controls throughout the year of the study but there was considerable between and within patient variation. No correlation was seen between TNF alpha and plasma noradrenaline, plasma renin activity, or weight. CONCLUSIONS The stimulus resulting in enhanced plasma concentrations of TNF alpha in congestive heart failure remains unclear and concentrations at any particular time were not prognostic.

Cite

CITATION STYLE

APA

Dutka, D. P., Elborn, J. S., Delamere, F., Shale, D. J., & Morris, G. K. (2007). Tumour necrosis factor alpha in severe congestive cardiac failure. Heart, 70(2), 141–143. https://doi.org/10.1136/hrt.70.2.141

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free